Sumitomo Chemical Company (4005) Q3 2026 earnings summary

Executive summary

• Core operating income and net income attributable to owners rose sharply year-over-year, surpassing forecasts, driven by strong pharma sales, robust segment performance, and gains from business divestitures.

• Significant improvements were seen in Sumitomo Pharma, Essential & Green Materials, and Agro & Life Solutions, with notable one-time gains and robust product sales.

• Sales revenue for Q3 FY2025 was ¥1,706.3 billion, down ¥198.5 billion year-over-year, but all profit categories increased significantly.

• Net income exceeded the third quarter forecast, but non-recurring losses are expected to concentrate in Q4.

• Upward revisions were made to the full-year forecast, with sales revenue now expected at ¥2,300.0 billion and net income attributable to owners of the parent at ¥55.0 billion.

Financial highlights

• Q3 FY2025 sales revenue was ¥1,706.3 billion, down 10.4% year-over-year; core operating income was ¥186.8 billion, up 211.1%.

• Net income attributable to owners of the parent reached ¥87.4 billion, a 205.7% increase year-over-year.

• Operating income reached ¥180.4 billion, up ¥35 billion year-on-year.

• Free cash flow for Q3 FY2025 was ¥71.8 billion, down from ¥197.5 billion year-over-year.

• Return on equity improved to 9.0% from 3.0% in the prior year.

Outlook and guidance

• Full-year FY2025 sales revenue forecast revised upward to ¥2,300.0 billion, core operating income to ¥200.0 billion, and net income attributable to owners of the parent to ¥55.0 billion.

• Annual dividend forecast raised to ¥13.5 per share, with a payout ratio of about 40%.

• ICT & Mobility Solutions segment profit guidance raised by ¥2 billion due to higher semiconductor material shipments.

• Profit from business activities expected to improve significantly due to structural reforms.